Table Cardiomagnyl n / v 75 + 15.2mg film 100 pcs

$5.07

Table Cardiomagnyl n / v 75 + 15.2mg film 100 pcs

Quantity:

Description

Composition
Active substance:
1 tablet contains: acetylsalicylic acid 75 g / 150 mg magnesium hydroxide 15.2 mg / 30.39 mg.
Excipients:
Corn starch 9.5 mg / 19.0 mg Microcrystalline cellulose 12.5 mg / 25.0 mg magnesium stearate 150 g / 305 g potato starch 2.0 mg / 4.0 mg. sheath: hypromellose (methylhydroxypropylcellulose 15) 460 mg / 1.2 mg propylene glycol 90 g / 240 g talc 280 g / 720 g.
Description:
Film-coated tablets containing 75 mg / 15.2 mg of acetylsalicylic acid and magnesium hydroxide, respectively: tablets, film-coated, white in the form of a stylized “heart”
Film-coated tablets containing 150 mg / 30.39 mg of acetylsalicylic acid and magnesium hydroxide, respectively: tablets, film-coated, white, oval-shaped with the notch on one side.
Product form:
Film-coated tablets 75 mg and 15.2 mg + 150 mg 30.39 mg 30 or 100 tablets in glass vials brown, sealed with screw cap, white (made of polyethylene), with a removable capsule mounted silica gel ring and providing a first control autopsy. On each vial label paste. One vial with instructions for use placed in a cardboard box.
Contraindications
Hypersensitivity to ASA, the drug and excipients other NSAIDs, cerebral hemorrhage; tendency to bleeding (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis); bronchial asthma induced by intake of salicylates and NSAIDs; erosive and ulcerative lesions of the gastrointestinal tract (exacerbation); gastrointestinal bleeding; severe renal failure (less than 10 ml / min creatinine clearance.); pregnancy (I and III trimester); lactation; deficiency of glucose-6-phosphate dehydrogenase; simultaneous with methotrexate (more than 15 mg per week); Children up to age 18 years.
Carefully
In gout, hyperuricemia, a history of ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding, kidney and / or liver failure, asthma, hay fever, nasal polyps, allergic conditions, in the II trimester of pregnancy.
Dosage
75 mg + 15.2 mg
Indications
Primary prevention of cardiovascular diseases such as thrombosis and congestive heart failure in the presence of risk factors (e.g., diabetes, hyperlipidemia, hypertension, obesity, smoking, old age). Preventing recurrent myocardial infarction and thrombosis of blood vessels. Prevention of thromboembolic events after surgical interventions on vessels (coronary artery bypass graft, percutaneous transluminal coronary angioplasty). Unstable angina.
Interaction with other drugs
With simultaneous use of ASA enhances the effect of the following drugs: methotrexate by reducing renal clearance and displace it from its association with proteins heparin anticoagulants due to abnormalities of platelet function and displacement anticoagulants from binding with proteins thrombolytic and antiplatelet and anticoagulant drugs (ticlopidine) of digoxin due to lower renal excretion its hypoglycemic agents for oral use (sulfonylurea derivatives) and insulin due hy oglikemicheskih properties of the ASA in high doses and displacement sulfonylurea derivatives of proteins due to blood plasma valproic acid due to displacement from its association with proteins simultaneous use of ASA with ibuprofen reduces the cardioprotective effects of ASA. An additive effect is observed while receiving ACK with ethanol (alcohol). ASA reduces the effect of uricosuric agents (benzbromaron) due tubular competitive elimination of uric acid. Leveraging the elimination of salicylates, systemic glucocorticosteroids (GCS) weaken their effect. Antacids and colestyramine reduce vsavyvanie preparation.
Overdose
Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment: gastric lavage, activated charcoal to take. Treatment is symptomatic. Symptoms of severe overdose: fever, hyperventilation, ketosis, respiratory alkalosis, coma, cardiovascular and respiratory insufficiency, severe hypoglycemia.
Treatment: immediate hospitalization in a specialized department for Emergency therapy – gastric lavage, determination of the acid-alkaline balance, alkaline and forced alkaline diuresis, dialysis, administration of solutions, activated carbon, symptomatic therapy. When conducting alkali diuresis values ​​necessary to achieve a pH between 7.5 and 8. Forced diuresis alkali should be performed when the salicylate concentration in plasma is greater than 500 mg / l (3.6 mmol / l) in adults and 300 mg / L (2, 2 mmol / l) in children.
pharmachologic effect
Pharmacological group:
Antiplatelet agent.
Pharmacodynamics:
Underlying mechanism of action of acetylsalicylic acid (ASA) is irreversible inhibition of cyclooxygenase (COX-1), resulting in blocked synthesis of thromboxane A2 and platelet aggregation is suppressed. It is believed that ASA has other mechanisms of platelet aggregation suppressant that expands the scope of its application in various vascular diseases. ASA has also anti-inflammatory, analgesic, antipyretic effect. Magnesium hydroxide, which is part of cardiomagnyl, protects the mucosa of the gastrointestinal tract from the effects of acetylsalicylic acid.
Pharmacokinetics:
ASA is absorbed from the gastrointestinal tract almost completely. ASA-life period is about 15 minutes, because involving enzymes ACK quickly hydrolyzed to salicylic acid (SA) in the intestines, the liver and blood plasma. The half-life is about SC 3 hours, but it may significantly increase, while a large dose of ASA (more than 3.0 g) as a result of saturation of enzyme systems. Bioavailability ASA is about 70%, but this value greatly fluctuates, because ASA is subjected to first-pass hydrolysis (mucous membrane of the gastrointestinal tract, liver) in the UK under the action of enzymes. SC Bioavailability of 80- 100%. The doses used the magnesium hydroxide does not affect the bioavailability of acetylsalicylic acid.
Pregnancy and breast-feeding
The use of high doses of salicylates in the first 3 months of pregnancy is associated with an increased rate of fetal defects. In the II trimester of pregnancy salicylates can be given only on the basis of strict risk assessment and benefit. In the last trimester of pregnancy salicylates in high dose (300 mg / day) cause inhibition of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and the fetus, and the destination just before birth can cause intracranial hemorrhage, especially in premature infants. Appointment of salicylates in the last trimester of pregnancy is contraindicated. The available clinical data are insufficient to determine the possibility or impossibility of the drug during breastfeeding. Before the appointment of acetylsalicylic acid during lactation should evaluate the potential benefits of therapy with respect to the potential risk to the infant.
Conditions of supply of pharmacies
Without recipe.
side effects
The frequency of adverse reactions listed below, was determined according to the following: -very often> 1/10; -Frequently> 1/100,
special instructions
The drug should be used when prescribing physician. ASA may provoke bronchospasm and also cause bronchial asthma and other hypersensitivity reactions. Risk factors are the availability of a history of asthma, hay fever, nasal polyposis, chronic diseases of the respiratory system as well as of allergic reactions to other drugs (e.g., skin reactions, pruritus, urticaria). ASA may cause bleeding of varying severity during and after surgery. A few days before the planned surgical intervention should be assessed the risk of bleeding when compared with the risk of ischemic events in patients taking low-dose ASA. If a significant risk of bleeding, ASA should be temporarily discontinued. The combination of ASA with an anticoagulant, thrombolytic and antiplatelet agents is accompanied by an increased risk of bleeding. ASA in low doses can trigger the development of gout in predisposed patients (having a reduced excretion of uric acid). The combination of ASA with MTX accompanied by increased incidence of side effects of hematopoiesis. High doses of ASA have a hypoglycemic effect, it is necessary to bear in mind when assigning it to patients with diabetes receiving hypoglycemic agents for oral and insulin. The combined application of systemic glucocorticosteroids (GCS) and salicylates should be remembered that during the treatment the blood concentration salicylates reduced and canceled after systemic glucocorticosteroids (GCS) can overdose salicylates. ASA is not recommended combination with ibuprofen in patients with an increased risk of cardiovascular disease: the simultaneous use of ibuprofen observed decrease antiagregatnogo action ASA in doses up to 300 mg, which reduces the cardioprotective effects of ASA. Excess dose ASA over recommended therapeutic dose is associated with the risk of gastrointestinal bleeding. Chronic administration of low-dose ASA as agregantnoy therapy requires caution in the elderly due to the risk of gastrointestinal bleeding. In simultaneous reception ACK alcohol increased the risk of damaging the mucosa of the gastrointestinal tract and prolongation of bleeding time.
Effects on ability to drive vehicles and moving machinery
In the period of treatment with ASA must be careful when driving and classes of potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In the dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
The tablets swallowed whole with water. If desired, the tablet can break in half, chewed or pre-grind.
Primary prevention of cardiovascular diseases such as thrombosis and congestive heart failure in the presence of risk factors (e.g., diabetes, hyperlipidemia, hypertension, obesity, smoking, advanced age) 1 tablet cardiomagnyl containing ASA in a dose of 150 mg on the first day, then 1 tablet cardiomagnyl containing ASA 75 mg 1 time per day.
Preventing recurrent myocardial infarction and thrombosis of blood vessels cardiomagnyl 1 tablet containing ASA in a dose of 75 – 150 mg 1 time per day.
Prevention of thromboembolic events after surgical interventions on vessels (coronary artery bypass graft, percutaneous transluminal coronary angioplasty) cardiomagnyl 1 tablet containing ASA in a dose of 75 – 150 mg 1 time per day.
Unstable angina cardiomagnyl 1 tablet containing ASA in a dose of 75 -150 mg 1 time per day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

TAKEDA

There are no reviews yet.

Add your review